tiprankstipranks
Trending News
More News >
Bridgebio Pharma (BBIO)
:BBIO
US Market
Advertisement

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

Compare
1,361 Followers
See the Price Targets and Ratings of:

BBIO Analyst Ratings

Strong Buy
19Ratings
Strong Buy
18 Buy
1 Hold
0 Sell
Based on 19 analysts giving stock ratings to
BridgeBio
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$63.35
▲(37.03%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $63.35 with a high forecast of $95.00 and a low forecast of $42.00. The average price target represents a 37.03% change from the last price of $46.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","96":"$96","41.25":"$41.3","59.5":"$59.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41.25,59.5,77.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,46.79692307692308,50.81384615384616,54.830769230769235,58.84769230769231,62.86461538461539,66.88153846153847,70.89846153846153,74.91538461538462,78.93230769230769,82.94923076923078,86.96615384615384,90.98307692307692,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,44.362307692307695,45.94461538461539,47.526923076923076,49.10923076923077,50.691538461538464,52.27384615384616,53.856153846153845,55.43846153846154,57.02076923076923,58.60307692307693,60.18538461538462,61.767692307692315,{"y":63.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.78,42.72,42.660000000000004,42.6,42.54,42.480000000000004,42.42,42.36,42.3,42.24,42.18,42.12,42.06,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$95.00Average Price Target$63.35Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BBIO
TipRanks AITipRanks
Not Ranked
TipRanks
$44
Hold
-4.82%
Downside
Reiterated
06/24/25
BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.
Cantor Fitzgerald Analyst forecast on BBIO
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$95
Buy
105.49%
Upside
Reiterated
07/29/25
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Raymond James Analyst forecast on BBIO
Martin AusterRaymond James
Raymond James
$57$56
Buy
21.13%
Upside
Initiated
07/29/25
BridgeBio assumed with an Outperform at Raymond JamesBridgeBio assumed with an Outperform at Raymond James
Piper Sandler Analyst forecast on BBIO
Biren AminPiper Sandler
Piper Sandler
$68
Buy
47.09%
Upside
Reiterated
07/25/25
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on BBIO
Danielle BrillTruist Financial
Truist Financial
$66
Buy
42.76%
Upside
Initiated
07/21/25
BridgeBio initiated with a Buy at TruistBridgeBio initiated with a Buy at Truist
H.C. Wainwright Analyst forecast on BBIO
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$56
Buy
21.13%
Upside
Reiterated
07/18/25
BridgeBio Pharma (BBIO) Receives a Buy from H.C. Wainwright
Wells Fargo Analyst forecast on BBIO
Tiago FauthWells Fargo
Wells Fargo
$76
Buy
64.40%
Upside
Reiterated
07/15/25
We rate shares Overweight.
Leerink Partners Analyst forecast on BBIO
Mani ForooharLeerink Partners
Leerink Partners
$53$56
Buy
21.13%
Upside
Reiterated
07/15/25
BridgeBio Pharma's Promising Diversification and High-Margin Opportunities Drive Buy Rating
Citi
$58$67
Buy
44.93%
Upside
Reiterated
07/14/25
BridgeBio Pharma's Promising Prospects: Buy Rating Driven by BBP-418's Potential in Rare Neuromuscular Disorder
Jefferies Analyst forecast on BBIO
Andrew TsaiJefferies
Jefferies
$70
Buy
51.42%
Upside
Initiated
07/14/25
BridgeBio Pharma (BBIO) Receives a Buy from Jefferies
Scotiabank Analyst forecast on BBIO
Greg HarrisonScotiabank
Scotiabank
$55
Buy
18.97%
Upside
Reiterated
07/14/25
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
Bank of America Securities Analyst forecast on BBIO
Jason ZemanskyBank of America Securities
Bank of America Securities
$54
Buy
16.81%
Upside
Reiterated
07/11/25
BridgeBio Pharma's Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA Support
BMO Capital Analyst forecast on BBIO
Kostas BiliourisBMO Capital
BMO Capital
$42
Hold
-9.15%
Downside
Reiterated
07/11/25
Cautious Hold Rating for BridgeBio Pharma Amid Attruby Sales Focus and BBP-418 Regulatory Prospects
Oppenheimer Analyst forecast on BBIO
Trevor AllredOppenheimer
Oppenheimer
$60
Buy
29.79%
Upside
Upgraded
07/09/25
BridgeBio upgraded to Outperform from Perform at OppenheimerBridgeBio upgraded to Outperform from Perform at Oppenheimer
TD Cowen
Buy
Reiterated
06/24/25
BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BBIO
TipRanks AITipRanks
Not Ranked
TipRanks
$44
Hold
-4.82%
Downside
Reiterated
06/24/25
BridgeBio Pharma benefits from strong technical momentum and positive earnings call with successful product launches and pipeline progress. However, financial performance and valuation concerns due to unprofitability and high leverage weigh heavily on the overall score.
Cantor Fitzgerald Analyst forecast on BBIO
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$95
Buy
105.49%
Upside
Reiterated
07/29/25
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
Raymond James Analyst forecast on BBIO
Martin AusterRaymond James
Raymond James
$57$56
Buy
21.13%
Upside
Initiated
07/29/25
BridgeBio assumed with an Outperform at Raymond JamesBridgeBio assumed with an Outperform at Raymond James
Piper Sandler Analyst forecast on BBIO
Biren AminPiper Sandler
Piper Sandler
$68
Buy
47.09%
Upside
Reiterated
07/25/25
Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on BBIO
Danielle BrillTruist Financial
Truist Financial
$66
Buy
42.76%
Upside
Initiated
07/21/25
BridgeBio initiated with a Buy at TruistBridgeBio initiated with a Buy at Truist
H.C. Wainwright Analyst forecast on BBIO
Ram SelvarajuH.C. Wainwright
H.C. Wainwright
$56
Buy
21.13%
Upside
Reiterated
07/18/25
BridgeBio Pharma (BBIO) Receives a Buy from H.C. Wainwright
Wells Fargo Analyst forecast on BBIO
Tiago FauthWells Fargo
Wells Fargo
$76
Buy
64.40%
Upside
Reiterated
07/15/25
We rate shares Overweight.
Leerink Partners Analyst forecast on BBIO
Mani ForooharLeerink Partners
Leerink Partners
$53$56
Buy
21.13%
Upside
Reiterated
07/15/25
BridgeBio Pharma's Promising Diversification and High-Margin Opportunities Drive Buy Rating
Citi
$58$67
Buy
44.93%
Upside
Reiterated
07/14/25
BridgeBio Pharma's Promising Prospects: Buy Rating Driven by BBP-418's Potential in Rare Neuromuscular Disorder
Jefferies Analyst forecast on BBIO
Andrew TsaiJefferies
Jefferies
$70
Buy
51.42%
Upside
Initiated
07/14/25
BridgeBio Pharma (BBIO) Receives a Buy from Jefferies
Scotiabank Analyst forecast on BBIO
Greg HarrisonScotiabank
Scotiabank
$55
Buy
18.97%
Upside
Reiterated
07/14/25
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
Bank of America Securities Analyst forecast on BBIO
Jason ZemanskyBank of America Securities
Bank of America Securities
$54
Buy
16.81%
Upside
Reiterated
07/11/25
BridgeBio Pharma's Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA Support
BMO Capital Analyst forecast on BBIO
Kostas BiliourisBMO Capital
BMO Capital
$42
Hold
-9.15%
Downside
Reiterated
07/11/25
Cautious Hold Rating for BridgeBio Pharma Amid Attruby Sales Focus and BBP-418 Regulatory Prospects
Oppenheimer Analyst forecast on BBIO
Trevor AllredOppenheimer
Oppenheimer
$60
Buy
29.79%
Upside
Upgraded
07/09/25
BridgeBio upgraded to Outperform from Perform at OppenheimerBridgeBio upgraded to Outperform from Perform at Oppenheimer
TD Cowen
Buy
Reiterated
06/24/25
BridgeBio Pharma (BBIO) Gets a Buy from TD Cowen
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

1 Month
xxx
Success Rate
8/15 ratings generated profit
53%
Average Return
+12.71%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +12.71% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
80%
Average Return
+27.51%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +27.51% per trade.
1 Year
Success Rate
18/20 ratings generated profit
90%
Average Return
+38.10%
reiterated a buy rating last month
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +38.10% per trade.
2 Years
xxx
Success Rate
20/21 ratings generated profit
95%
Average Return
+93.99%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +93.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
10
16
14
15
10
Buy
27
26
17
17
22
Hold
2
1
2
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
43
33
39
39
In the current month, BBIO has received 32 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 63.35.
Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.77 with a range of -$1.10 to -$0.40. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.
Next quarter’s earnings estimate for BBIO is -$0.77 with a range of -$1.10 to -$0.40. The previous quarter’s EPS was -$0.88. BBIO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.95% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $92.16M with a range of $54.73M to $182.40M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.
Next quarter’s sales forecast for BBIO is $92.16M with a range of $54.73M to $182.40M. The previous quarter’s sales results were $116.63M. BBIO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year BBIO has Preformed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Bridgebio Pharma’s 12-month average price target is 63.35.
    What is BBIO’s upside potential, based on the analysts’ average price target?
    Bridgebio Pharma has 37.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBIO a Buy, Sell or Hold?
          Bridgebio Pharma has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Bridgebio Pharma’s price target?
            The average price target for Bridgebio Pharma is 63.35. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $95.00 ,the lowest forecast is $42.00. The average price target represents 37.03% Increase from the current price of $46.23.
              What do analysts say about Bridgebio Pharma?
              Bridgebio Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of BBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis